TickerFacts.

Company research / AMPH

Amphastar Pharmaceuticals, Inc. (AMPH)

Build a valuation ↗↓ Download CSV

CIK 0001297184 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Amphastar Pharmaceuticals, Inc. reported revenue of $719.89M. Revenue fell 1.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $730.02M.

Key ratios (year ended 2025-12-31)

49.5%
Gross margin
19.5%
Operating margin
13.6%
Net margin
12.4%
Return on year-end equity
-1.7%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-23

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$730.02M$719.89M$731.97M$644.39M$498.99M$437.77M$349.85M$322.36M$294.67M$240.18M$255.16M
Cost of Revenue$381.91M$363.83M$358.11M$293.27M$250.13M$238.03M$206.51M$190.43M$187.68M$149.67M$150.97M
Gross Profit$348.11M$356.06M$373.86M$351.12M$248.86M$199.74M$143.34M$131.92M$106.98M$90.51M$104.20M
R&D Expense$94.57M$85.84M$73.91M$73.74M$74.77M$60.93M$67.23M$68.85M$57.56M$43.50M$41.52M
Operating Income$114.28M$140.40M$205.42M$196.99M$107.50M$69.89M$10.95M-$39.0K-$8.62M-$1.27M$15.38M
Depreciation & Amortizationn/an/an/a$25.74M$12.60M$10.22M$9.03M$7.06M$6.05M$6.42Mn/a
EBITDAn/an/an/a$222.72M$120.09M$80.11M$19.98M$7.02M-$2.57M$5.15Mn/a
Net Income$78.55M$98.09M$159.52M$137.54M$91.39M$62.12M$1.40M$48.94M-$5.74M$3.65M$9.82M
EPS (Diluted)n/a$2.03$3.06$2.60$1.74$1.25$0.03$0.98-$0.12$0.08$0.21
Total Assets$1.74B$1.63B$1.58B$1.51B$741.99M$671.53M$631.24M$586.97M$513.56M$451.07M$427.74M
Total Liabilities$975.61M$840.49M$845.17M$873.49M$213.33M$226.01M$182.51M$159.44M$149.20M$117.34M$98.48M
Shareholders' Equity$768.16M$788.80M$732.30M$639.42M$528.66M$445.52M$448.72M$427.53M$364.36M$333.74M$326.52M
Cash & Equivalents$223.61M$170.18M$151.61M$144.30M$156.10M$126.35M$92.64M$73.69M$86.34M$65.59M$72.35M
Operating Cash Flow$184.61M$156.12M$213.39M$183.50M$89.18M$97.99M$57.27M$41.76M$38.19M$39.21M$38.56M
Capital Expenditures$31.72M$34.88M$41.04M$38.17M$24.03M$27.46M$33.85M$41.55M$46.81M$35.10M$21.38M
Free Cash Flow$152.89M$121.23M$172.34M$145.34M$65.15M$70.54M$23.41M$207.0K-$8.62M$4.11M$17.18M
Share Repurchases$100.07M$75.59M$85.46M$58.14M$39.91M$28.87M$24.43M$22.29M$25.05M$30.75M$9.91M
Shares Outstanding42.53M45.65M47.62M48.07M48.11M47.71M47.50M46.58M46.63M46.62M46.25M
Weighted Average Diluted Sharesn/a48.22M52.06M53.00M52.43M49.78M49.12M49.91M46.40M48.37M47.50M
EPS (Basic)n/a$2.10$3.29$2.85$1.88$1.30$0.03$1.04-$0.12$0.08$0.22

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView